166 related articles for article (PubMed ID: 37385234)
1. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
[TBL] [Abstract][Full Text] [Related]
2. Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging.
Thormann M; Surov A; Pech M; March C; Hass P; Damm R; Omari J
Acta Radiol; 2023 Apr; 64(4):1331-1340. PubMed ID: 36262039
[TBL] [Abstract][Full Text] [Related]
3. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
4. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
5. Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma.
Song Z; Ye J; Wang Y; Li Y; Wang W
J Cancer Res Ther; 2019; 15(7):1553-1560. PubMed ID: 31939437
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment.
Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto R; Tanaka H; Kobayashi Y; Mizuno S; Nakagawa H
Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1269-1276. PubMed ID: 36317773
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy.
Thormann M; Heitmann F; Wrobel V; Barajas Ordonez F; Pech M; Surov A; Damm R; Omari J
Rofo; 2023 Mar; 195(3):217-223. PubMed ID: 36283404
[TBL] [Abstract][Full Text] [Related]
8.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
9. Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules.
Heinze C; Damm R; Othmer M; Thormann M; Surov A; Hass P; Seidesticker R; Seidensticker M; Ricke J; Powerski M; Pech M; Omari J
Brachytherapy; 2023; 22(2):231-241. PubMed ID: 36697267
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer.
Liu X; Hou Y; Wang X; Yu L; Wang X; Jiang L; Yang Z
Hepatol Int; 2020 Jul; 14(4):567-576. PubMed ID: 32556865
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area.
Faron A; Sprinkart AM; Pieper CC; Kuetting DLR; Fimmers R; Block W; Meyer C; Thomas D; Attenberger U; Luetkens JA
Eur J Radiol; 2020 Apr; 125():108889. PubMed ID: 32087468
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
15. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
[TBL] [Abstract][Full Text] [Related]
16. CT-guided
Chen Z; Fu X; Qiu Z; Mu M; Jiang W; Wang G; Zhong Z; Qi H; Gao F
Radiol Oncol; 2023 Mar; 57(1):127-139. PubMed ID: 36942903
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
18. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
[TBL] [Abstract][Full Text] [Related]
19. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
